鴻盛昌資源(01850.HK)完成配售2880萬股 淨籌約1851.7萬港元
格隆匯5月17日丨鴻盛昌資源(01850.HK)宣佈,配售協議載列的所有條件已獲達成,而完成已於2024年5月16日落實。配售代理已根據配售協議之條款及條件,以配售價每股配售股份0.67港元成功向不少於六名承配人配售合共2880萬股配售股份。2880萬股配售股份相當於公吿日期緊接完成前公司現有已發行股本的約20.0%,及經配售股份擴大之本公司已發行股本的約16.67%。
配售事項所得款項總額約為1929.6萬港元,而配售事項的所得款項淨額約為1851.7萬港元。公司擬將配售事項的所得款項淨額當中約300萬港元用作償還股東貸款、約1100萬港元用作業務擴展以及餘下用作集團的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.